TECH at a glance
Bio-Techne (TECH, SEC CIK 842023) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Bio-Techne (TECH) shares worth $4.6 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.2B
- −0.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $4.6B · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Business Overview
- Core business model: Develop, manufacture, and sell life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally
- New emphasis on Diagnostics and Spatial Biology segment with Lunaphore acquisition in fiscal 2024 enhancing automated spatial biology solutions
- Strategic move toward integration as Merck KGaA merger announced in June 2026 with $73.00/share cash offer, expected closing late 2026/early 2027
- Employee base steady at ~3,000 globally with 48% female and 22% nonwhite representation; 1,900+ new products introduced in fiscal 2026
- Diagnostics and Spatial Biology segment now ~28% of net revenues, reflecting increased focus and expansion into adjacent diagnostics markets
Risk Factors
- Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability
- Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs
- Operational risk: Sole or limited source suppliers and complex FDA-regulated manufacturing may cause production delays and capacity constraints
- Competitive risk: Lunaphore spatial biology solutions acquisition targets rapid innovation, but competitive pressure from multinational and start-ups persists
- Financial risk: $200M drawn on $1B revolving credit facility with covenants limiting transactions, increasing vulnerability to economic or interest rate changes
Management Discussion & Analysis
- Revenue $1.215B, flat YoY (FY26 vs. FY25); Protein Sciences up 1% to $874.6M, Diagnostics down 3% to $336.4M
- Operating gross margin 65.8% vs 64.8%, adjusted gross margin 69.6% vs 70.4%; Protein Sciences margin 75.0% vs 75.6%, Diagnostics margin 55.2% vs 57.3%
- Best segment Protein Sciences: sales $874.6M, +1% YoY; worst Diagnostics: sales $336.4M, -3% YoY, impacted by held-for-sale business divestiture
- Cash flow from operations $292.1M; dividends paid $49.9M; share repurchases $41.7M; capex $28.9M; cash & investments $264.7M, up from $162.2M
- Merger agreement signed with Merck KGaA for $73/share cash buyout; merger expected late 2026 or early 2027; execution subject to regulatory and shareholder approvals
AI summary of the TECH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $299.7M, up 5% YoY from $286.6M
- Gross margin 65.6% vs 65.6% YoY, adjusted margin 69.3% vs 70.2%
- Protein Sciences best performer: sales $219.7M, up 9%; operating margin 37.9% vs 38.4%
- Diagnostics and Spatial Biology weakest: sales $80.2M, up 1%; operating margin 7.4% vs 11.2%
- Cash $350.0M vs $264.7M; operating cash flow $73.1M vs $27.6M, capital expenditures $5.9M and $12.6M dividends
Risk Factors
- No material changes to previously disclosed risk factors during the quarter ended September 30, 2026
- Carried-forward risks include macroeconomic conditions affecting demand and operating results
- Carried-forward risks include competition and technological change in life-science markets
- Carried-forward risks include liquidity, debt, and foreign-currency exposure
AI summary of the TECH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Bio-Techne announced a cash dividend in its November 3, 2026 press release
- Dividend announcement signals a direct shareholder return and may affect income-oriented investor expectations
Item EX-99.1: Item EX-99.1
- Quarterly dividend: $0.08 per share for the quarter ended September 30, 2026
- Payment November 23, 2026 to shareholders of record November 13, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger approved by shareholders, clearing a key condition for Merck KGaA’s acquisition of Bio-Techne
- 121.93M votes for versus 1.21M against, with 30,610 abstentions
Item EX-99.1: Item EX-99.1
- Shareholders approved Merck KGaA’s proposed acquisition, removing a key transaction condition
- Hart-Scott-Rodino waiting period expired September 18, 2026, reducing U.S. antitrust execution risk
Item 7.01: Regulation FD Disclosure
- Shareholders approved the Merger Agreement Proposal on September 23, 2026
- Approval clears the shareholder voting condition for Bio-Techne’s proposed merger
Item 5.02: Departure/Appointment of Directors or Principal Officers
- References February 11, 2026 Form 8-K for officer appointments and compensation arrangements
- Executive and director ownership changes reported through SEC Forms 3 or 4
Item 8.01: Other Events
- Merger litigation emerged: shareholder lawsuit seeks to enjoin the September 23, 2026 vote, creating execution and timing risk
- Multiple demand letters challenge proxy disclosures, though Bio-Techne disputes the allegations and estimates no potential loss
AI summaries of TECH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TECH
Don't miss the next TECH filing
- Alerts as it files. A push when TECH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TECH, by share count.
- Ask anything. An AI agent that reads every TECH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hippel James | F | Nov 1, 2026 | 5,096 | $72.66 |
| Hippel James | M | Nov 1, 2026 | 11,545 | - |
| Hippel James | M | Nov 1, 2026 | 11,545 | - |
| Kelderman Kim | F | Nov 1, 2026 | 2,385 | $72.66 |
| Vessey Rupert | A | Oct 29, 2026 | 2,750 | - |
| BAUMGARTNER ROBERT V | A | Oct 29, 2026 | 2,750 | - |
| Herr Amy E. | A | Oct 29, 2026 | 2,750 | - |
| Bushman Julie L | A | Oct 29, 2026 | 2,750 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.2B |
| Gross Profit | - | $790.3M | $799.1M |
| Operating Income | - | $102.3M | $251.9M |
| Net Income | - | $73.4M | $181.8M |
| Gross Margin | - | 64.8% | 65.8% |
| Op. Margin | - | 8.4% | 20.7% |
| Net Margin | - | 6.0% | 15.0% |
| Balance Sheet | |||
| Total Assets | $2.7B | $2.6B | $2.6B |
| Equity | - | $1.9B | $2.1B |
| ROE | - | 3.8% | 8.6% |
| Per Share | |||
| EPS | - | $0.46 | $1.16 |
| Cash Flow | |||
| Operating CF | - | $287.6M | $292.1M |
| CapEx | $62.9M | $31.0M | $28.9M |
Source: XBRL data in Bio-Techne (TECH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TECH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $4.59B |
| Q2 2026 | 37 | $5.75B |
| Q1 2026 | 35 | $3.76B |
| Q4 2025 | 30 | $3.97B |
| Q3 2025 | 32 | $3.61B |
| Q2 2025 | 31 | $3.86B |
| Q1 2025 | 27 | $2.94B |
| Q4 2024 | 24 | $3.15B |
- Millennium Management+3.10M (+314%)
- D.E. Shaw & Co+2.30M (+1008%)
- Citigroup+1.32M (+295%)
- Two Sigma Investments+231.8K (+333%)
- BlackRock+224.6K (+2%)
- Goldman Sachs Group−3.20M (-44%)
- Morgan Stanley−3.05M (-48%)
- Dimensional Fund Advisors−1.67M (-74%)
- Invesco Ltd−1.21M (-24%)
- Citadel Advisors LLC−855.0K (-89%)
- Renaissance Technologies LLC+12.9K
- StoneX Group Inc.+10.6K
- FMR LLC (Fidelity)−12.79M
- Soros Fund Management−535.4K
- Bridgewater Associates LP−26.8K
- Regions Financial Corporation−9.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 251 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TECH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 10-K | Aug 24, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TECH SEC filings: frequently asked questions
Which institutions hold TECH stock?
As of September 30, 2026, the largest Bio-Techne (TECH) holders among the 13F filers tracked by SignalX were BlackRock ($1.0 billion), Vanguard Capital Management LLC ($742.9 million), Vanguard Portfolio Management LLC ($460.1 million), State Street Corp ($438.1 million), Goldman Sachs Group ($300.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TECH's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16. The figures come from the XBRL data in the 10-K.
What are the main risks in TECH's latest 10-K?
In the 10-K filed August 24, 2026, Bio-Techne (TECH) flagged: Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability. Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs. (AI summary of the Risk Factors section.)
What did TECH report in its latest 8-K?
Bio-Techne (TECH) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events). Bio-Techne announced a cash dividend in its November 3, 2026 press release.
What are the latest TECH SEC filings?
Bio-Techne (TECH) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 3, 2026.
What is TECH's SEC CIK number?
Bio-Techne (TECH)'s SEC Central Index Key (CIK) is 842023. EDGAR lists every TECH filing under that number.
Ask anything about TECH
The research agent reads TECH's filings, financials, insider trades and 13F holders, then answers with sources.